Literature DB >> 9238051

Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.

L E Benjamin1, E Keshet.   

Abstract

We have recently shown that VEGF functions as a survival factor for newly formed vessels during developmental neovascularization, but is not required for maintenance of mature vessels. Reasoning that expanding tumors contain a significant fraction of newly formed and remodeling vessels, we examined whether abrupt withdrawal of VEGF will result in regression of preformed tumor vessels. Using a tetracycline-regulated VEGF expression system in xenografted C6 glioma cells, we showed that shutting off VEGF production leads to detachment of endothelial cells from the walls of preformed vessels and their subsequent death by apoptosis. Vascular collapse then leads to hemorrhages and extensive tumor necrosis. These results suggest that enforced withdrawal of vascular survival factors can be applied to target preformed tumor vasculature in established tumors. The system was also used to examine phenotypes resulting from over-expression of VEGF. When expression of the transfected VEGF cDNA was continuously "on," tumors became hyper-vascularized with abnormally large vessels, presumably arising from excessive fusions. Tumors were significantly less necrotic, suggesting that necrosis in these tumors is the result of insufficient angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9238051      PMCID: PMC23118          DOI: 10.1073/pnas.94.16.8761

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

2.  Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth.

Authors:  M S O'Reilly; L Holmgren; Y Shing; C Chen; R A Rosenthal; Y Cao; M Moses; W S Lane; E H Sage; J Folkman
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

3.  Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion.

Authors:  U Modlich; F J Kaup; H G Augustin
Journal:  Lab Invest       Date:  1996-04       Impact factor: 5.662

Review 4.  Programmed cell death and the control of cell survival.

Authors:  M C Raff; B A Barres; J F Burne; H S Coles; Y Ishizaki; M D Jacobson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1994-08-30       Impact factor: 6.237

Review 5.  Programmed cell death and the control of cell survival: lessons from the nervous system.

Authors:  M C Raff; B A Barres; J F Burne; H S Coles; Y Ishizaki; M D Jacobson
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

6.  Proliferative potential of vascular components in human glioblastoma multiforme.

Authors:  T Nagashima; T Hoshino; K G Cho
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

7.  Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.

Authors:  J M Isner; A Pieczek; R Schainfeld; R Blair; L Haley; T Asahara; K Rosenfield; S Razvi; K Walsh; J F Symes
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

8.  Expression of vascular endothelial growth factor in capillary hemangioblastoma.

Authors:  K Morii; R Tanaka; K Washiyama; T Kumanishi; R Kuwano
Journal:  Biochem Biophys Res Commun       Date:  1993-07-30       Impact factor: 3.575

9.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

10.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

View more
  93 in total

1.  Control of apoptosis during angiogenesis by survivin expression in endothelial cells.

Authors:  D S O'Connor; J S Schechner; C Adida; M Mesri; A L Rothermel; F Li; A K Nath; J S Pober; D C Altieri
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  VEGF expression by epithelial and stromal cell compartments: resolving a controversy.

Authors:  D R Senger; L Van De Water
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

3.  Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice.

Authors:  A Gilead; M Neeman
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

4.  Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription.

Authors:  Guangqi E; Ying Cao; Santanu Bhattacharya; Shamit Dutta; Enfeng Wang; Debabrata Mukhopadhyay
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 5.  Causes and effects of heterogeneous perfusion in tumors.

Authors:  R J Gillies; P A Schornack; T W Secomb; N Raghunand
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

6.  Transcription-controlled gene therapy against tumor angiogenesis.

Authors:  Shoshana Greenberger; Aviv Shaish; Nira Varda-Bloom; Keren Levanon; Eyal Breitbart; Iris Goldberg; Iris Barshack; Israel Hodish; Niva Yaacov; Livnat Bangio; Tanya Goncharov; David Wallach; Dror Harats
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

7.  Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

Authors:  Stefano Indraccolo; Laura Stievano; Sonia Minuzzo; Valeria Tosello; Giovanni Esposito; Erich Piovan; Rita Zamarchi; Luigi Chieco-Bianchi; Alberto Amadori
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

8.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael Leblanc; Richard I Fisher; Thomas P Miller
Journal:  Leuk Lymphoma       Date:  2009-05

9.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.

Authors:  R K Jain; N Safabakhsh; A Sckell; Y Chen; P Jiang; L Benjamin; F Yuan; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 10.  Central nervous system capillary haemangioblastoma: the pathologist's viewpoint.

Authors:  Mahmoud R Hussein
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.